Home Business & Economics

Business & Economics

Boehringer Ingelheim Venture Fund and PPF Group Close a US $ 22M Series C...

Privately-owned Swiss biotech company NBE-Therapeutics confirmed closing of a US $ 22M Series C financing round. The financing round...

James Panek Joins Sutro Biopharma’s Board of Directors

James P. Panek, an independent consultant since 2011, providing technical and strategic insights to companies around the world, has...
Featured Image - Laboratory. Courtesy 2019 Fotolia

Shanghai Miracogen and Synaffix Confirm Expansion of License Agreement

Netherlands-based biotech company Synaffix earlier today confirmed the expansion of a license agreement with Shanghai Miracogen, a Chinese biotechnology...

FDA Approves Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-positive Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca)*, a HER2 directed...

Accelerated Approval for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

The U.S. Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (Padcev™; Astellas Pharma / Seattle Genetics)*...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Immunomedics Resubmits BLA for Sacituzumab Govitecan

In a statement earlier today, Immunomedics confirmed that the company resubmitted its Biologics License Application (BLA) to the U.S....

ADC Express: Rapid ADC Production from a Single Source

Earlier this year, during the 10th annual World ADC meeting held in San Diego, CA, MilliporeSigma, launched a new...

SOTIO and NBE-Therapeutics to Develop ‘Second’ Next-Generation Antibody-Drug Conjugate

SOTIO, a biotechnology company leading the efforts of PPF Group, one of the largest investment groups in Central and...
Daiichi Sankyo

Daiichi Sankyo to Defend Proprietary Antibody-drug Conjugate Technology

Daiichi Sankyo confirmed that the company has filed a Declaratory Judgement action in the District Court of Delaware in...
Signing Ceremony between Ambrx an NovoCodex. Courtesy 2019 NovoCodex.

Ambrx and Novocodex to Jointly Develop and Commercialize 2nd Antibody-drug Conjugate

Novocodex Biopharmaceuticals, a subsidiary of Zhejiang Medicine, and  Ambrx, a privately-held clinical stage biopharmaceutical company, have confirmed that the...